FDA — authorised 3 July 2008
- Application: NDA022090
- Marketing authorisation holder: BAYER HLTHCARE
- Local brand name: EOVIST
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA authorised Eovist on 3 July 2008
Yes. FDA authorised it on 3 July 2008.
BAYER HLTHCARE holds the US marketing authorisation.